N9986

A phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia

Neil Elliot Kay, Tait D. Shanafelt, Timothy G. Call, Wenting Wu, Betsy R. Laplant

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We enrolled 28 eligible patients with relapsed chronic lymphocytic leukemia (CLL) to a phase II study of single agent thalidomide (200 mg/ d, with dose escalation up to 1000- mg/d over 60 days). The median age was 66 years and 71% were males. Study participants received a median of 2 (range 1-7) prior treatment regimens and 61% had Rai stage 3-4 disease at enrollment. Grade 3 or higher hematologic toxicity was observed in 13 (46%) and 16 (57%) had grade 3 or higher non-hematologic toxicity. Grade 3-4 tumor flare was observed in five (18%) patients. The overall response rate was 11% (3 of 28) with one (4%) complete remission and two (7%) partial remissions. Duration of response for these three responders was 3, 14 and 15 months. Fourteen (50%) patients had stabilisation of disease for a median duration of 8 months (95% CI: 7-16 months). Median time to progression for all 28 patients was 7.3 months. Although thalidomide appears to have modest clinical activity in pretreated/ relapsed CLL primarily based on reduction of the absolute lymphocyte count, in our opinion the toxicity profile precludes it from more active investigation in CLL.

Original languageEnglish (US)
Pages (from-to)588-592
Number of pages5
JournalLeukemia and Lymphoma
Volume50
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Thalidomide
B-Cell Chronic Lymphocytic Leukemia
Lymphocyte Count
Neoplasms
Therapeutics

Keywords

  • Angiogenesis
  • CLL
  • Relapsed
  • Thalidomide
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

N9986 : A phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. / Kay, Neil Elliot; Shanafelt, Tait D.; Call, Timothy G.; Wu, Wenting; Laplant, Betsy R.

In: Leukemia and Lymphoma, Vol. 50, No. 4, 2009, p. 588-592.

Research output: Contribution to journalArticle

Kay, Neil Elliot ; Shanafelt, Tait D. ; Call, Timothy G. ; Wu, Wenting ; Laplant, Betsy R. / N9986 : A phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 4. pp. 588-592.
@article{ce006138d73444b4b9aa27ed4d26efea,
title = "N9986: A phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia",
abstract = "We enrolled 28 eligible patients with relapsed chronic lymphocytic leukemia (CLL) to a phase II study of single agent thalidomide (200 mg/ d, with dose escalation up to 1000- mg/d over 60 days). The median age was 66 years and 71{\%} were males. Study participants received a median of 2 (range 1-7) prior treatment regimens and 61{\%} had Rai stage 3-4 disease at enrollment. Grade 3 or higher hematologic toxicity was observed in 13 (46{\%}) and 16 (57{\%}) had grade 3 or higher non-hematologic toxicity. Grade 3-4 tumor flare was observed in five (18{\%}) patients. The overall response rate was 11{\%} (3 of 28) with one (4{\%}) complete remission and two (7{\%}) partial remissions. Duration of response for these three responders was 3, 14 and 15 months. Fourteen (50{\%}) patients had stabilisation of disease for a median duration of 8 months (95{\%} CI: 7-16 months). Median time to progression for all 28 patients was 7.3 months. Although thalidomide appears to have modest clinical activity in pretreated/ relapsed CLL primarily based on reduction of the absolute lymphocyte count, in our opinion the toxicity profile precludes it from more active investigation in CLL.",
keywords = "Angiogenesis, CLL, Relapsed, Thalidomide, Treatment",
author = "Kay, {Neil Elliot} and Shanafelt, {Tait D.} and Call, {Timothy G.} and Wenting Wu and Laplant, {Betsy R.}",
year = "2009",
doi = "10.1080/10428190902777467",
language = "English (US)",
volume = "50",
pages = "588--592",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - N9986

T2 - A phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

AU - Call, Timothy G.

AU - Wu, Wenting

AU - Laplant, Betsy R.

PY - 2009

Y1 - 2009

N2 - We enrolled 28 eligible patients with relapsed chronic lymphocytic leukemia (CLL) to a phase II study of single agent thalidomide (200 mg/ d, with dose escalation up to 1000- mg/d over 60 days). The median age was 66 years and 71% were males. Study participants received a median of 2 (range 1-7) prior treatment regimens and 61% had Rai stage 3-4 disease at enrollment. Grade 3 or higher hematologic toxicity was observed in 13 (46%) and 16 (57%) had grade 3 or higher non-hematologic toxicity. Grade 3-4 tumor flare was observed in five (18%) patients. The overall response rate was 11% (3 of 28) with one (4%) complete remission and two (7%) partial remissions. Duration of response for these three responders was 3, 14 and 15 months. Fourteen (50%) patients had stabilisation of disease for a median duration of 8 months (95% CI: 7-16 months). Median time to progression for all 28 patients was 7.3 months. Although thalidomide appears to have modest clinical activity in pretreated/ relapsed CLL primarily based on reduction of the absolute lymphocyte count, in our opinion the toxicity profile precludes it from more active investigation in CLL.

AB - We enrolled 28 eligible patients with relapsed chronic lymphocytic leukemia (CLL) to a phase II study of single agent thalidomide (200 mg/ d, with dose escalation up to 1000- mg/d over 60 days). The median age was 66 years and 71% were males. Study participants received a median of 2 (range 1-7) prior treatment regimens and 61% had Rai stage 3-4 disease at enrollment. Grade 3 or higher hematologic toxicity was observed in 13 (46%) and 16 (57%) had grade 3 or higher non-hematologic toxicity. Grade 3-4 tumor flare was observed in five (18%) patients. The overall response rate was 11% (3 of 28) with one (4%) complete remission and two (7%) partial remissions. Duration of response for these three responders was 3, 14 and 15 months. Fourteen (50%) patients had stabilisation of disease for a median duration of 8 months (95% CI: 7-16 months). Median time to progression for all 28 patients was 7.3 months. Although thalidomide appears to have modest clinical activity in pretreated/ relapsed CLL primarily based on reduction of the absolute lymphocyte count, in our opinion the toxicity profile precludes it from more active investigation in CLL.

KW - Angiogenesis

KW - CLL

KW - Relapsed

KW - Thalidomide

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=68449101813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449101813&partnerID=8YFLogxK

U2 - 10.1080/10428190902777467

DO - 10.1080/10428190902777467

M3 - Article

VL - 50

SP - 588

EP - 592

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -